Navigation Links
Sanofi-aventis enters into a research and development collaboration with UCSF
Date:1/12/2011

Paris, France - January 12, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and the University of California, San Francisco (UCSF) have formed two research and development collaborations that join together leaders from academia and industry to more rapidly advance groundbreaking innovation from the lab to the patient. The first is an oncology partnership that will focus on project-based collaboration to accelerate research progress through the clinical proof of concept stage. The second collaboration promotes innovative research in pharmacological science and in multiple therapeutic areas, such as oncology, aging, diabetes and inflammation.

Sanofi-aventis will be the first industry partner for UCSF's Program for Breakthrough Biomedical Research (PBBR). The PBBR program awards funding to projects of potentially high impact and greater creativity, which offer an innovative approach to scientific discovery. The partnership with UCSF enhances sanofi-aventis' approach of setting up a unique structure revolving around networks of creativity spread across regions, technologies and scientific areas of excellence.

Under the terms of the agreement, a UCSF/sanofi-aventis Joint Steering Committee will choose from among UCSF-generated proposals identified for their scientific excellence. Sanofi-aventis will fund up to five grants a year, making additional funds available for student or fellow interns at sanofi-aventis to conduct collaborative research. To further this exchange of ideas, sanofi-aventis will fund an annual research forum bringing together sanofi-aventis and UCSF researchers to share knowledge and perspectives on relevant scientific matters and to review progress of research projects funded through the collaboration.

"As the largest public biomedical research institution in America, UCSF is dedicated to accelerating the translation of leading-edge research into state-of-the-art care for patients," said UCSF Chancellor Susan Desmond-Hellmann, MD, MPH. "This collaboration will help support ground-breaking projects that could offer the greatest possibilities in each of these fields."

"Joining forces with UCSF researchers emphasizes sanofi-aventis' commitment to establish strong relationships and collaborations with the best innovators in the world," said Christopher A. Viehbacher, Chief Executive Officer, sanofi-aventis. "By promoting open and deep scientific exchange between UCSF's leading researchers and sanofi-aventis' drug development experts, we aim to generate significant healthcare advances in multiple therapeutic areas, to discover and develop comprehensive healthcare solutions for patients."


'/>"/>

Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Related biology news :

1. Dana-Farber and sanofi-aventis establish cancer research alliance
2. NINDS awards new Udall Centers for Parkinsons Disease Research
3. Blood-thinning copycat enters malaria fight
4. DFG approves 12 new collaborative research centers
5. Concord Medical Enters Agreement to Acquire Four Radiotherapy and Diagnostic Imaging Centers in Hebei Province
6. Oxford University Press enters publishing partnership with Infectious Diseases Society of America
7. DFG approves funding for 17 new collaborative research centers
8. Graffinity Enters into Drug Discovery Research Collaboration with Genentech
9. NIH expands Human Microbiome Project; funds sequencing centers and disease projects
10. BIO-key(R) Enters Strategic Partnership With Nlets
11. BIO-key(R) Enters Strategic Partnership With Nlets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... UTAH. (PRWEB) , ... May 25, 2016 , ... WEDI, ... healthcare information exchange, today announced that Charles W. Stellar has been named by the ... interim CEO since January 2016. As an executive leader with more than 35 years ...
(Date:5/24/2016)... ... , ... Last week, Callan Capital, an integrated wealth management firm specializing in ... San Diego Life Science event at the Estancia La Jolla Resort and Spa. , ... speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former ...
(Date:5/23/2016)... , May 23, 2016 Oxitec CEO ... th at 10:15 a.m. ET before the United States ... genetically engineered mosquitos can play in controlling the spread of ... the Zika virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ... mosquito with a self-limiting gene. Trials in Brazil ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology: